Cartherics is delighted to be featured in the June 2025 issue of Pharma Technology Focus, drawing attention to our innovative approach to cell therapy. Unlike traditional cell therapies, Cartherics employs gene-edited natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) from umbilical cord blood.

This approach aims to enhance the immune system’s ability to target and destroy solid tumours, endometriosis, and potentially neurological diseases. CEO Professor Alan Trounson discusses the company’s advancements and the potential impact on the future of immunotherapy.  Read it here: https://pharma.nridigital.com/pharma_jun25/cartherics_company_insight